RARA and prostate carcinoma: One possible explanation of the growth inhibitory activities of both agonists and antagonists against prostate carcinoma cells is that agonism of RARα drives gene expression leading to cell growth arrest, but also that antagonism of RARγ switches off expression of a molecule(s) that plays a role in facilitating cell proliferation.